GRP logo
Budget Impact Analysis Good Practices

Principles of Good Practice for Budget Impact Analysis II: Report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis

The citation for this report is:
Sullivan SD, Mauskopf JA, Augustovski F, et al. Principles of good practice for budget impact analysis II: Report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis. Value Health 2014:17:5-14

Review: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force

Wim G. Goettsch, PhD, MSc, Health Care Insurance Board(CVZ), Diemen, The Netherlands

Editorial: Improving the Usefulness of Budget Impact Analyses: A U.S. Payer Perspective

John B. Watkins, PharmD, MPH, BCPS & Dan Danielson, MS, RPh Premera Blue Cross, Mountlake Terrace, WA,USA

Webinars Icon » Webinar



ISPOR Science Policy Brief

(English | Español | Português)

Translations:
» Български | » Español | » Slovenský

 

Leadership Group:
Josephine Mauskopf, PhD, (Task Force Co-Chair), Vice President of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
Sean Sullivan, PhD, (Task Force Co-Chair), Professor and Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
Federico Augustovski MD, MSc, PhD, Director, Health Economic Evaluation and Technology Assessment, Institute for Clinical Effectiveness and Health Policy (IECS); Professor of Public Health, Universidad de Buenos Aires, Buenos Aires, Argentina
J. Jaime Caro MDCM, FRCPC, FACP, Senior Vice President, Research, United BioSource Corporation, Lexington, MA, USA, and Adjunct Professor of Medicine & Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada
Karen Lee, MA, Director, Health Economics, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada
Mark Minchin, MBA, Technical Adviser – PASLU, National Institute for Health and Clinical Excellence, Manchester, United Kingdom
Ewa Orlewska, PhD, MD, Director, Centre for Pharmacoeconomics c/o NU Horizons, Warsaw, Poland
Pete Penna, PharmD, Principal and Co-founder, Formulary Resources, LLC, Mercer Island, WA
Jose-Manuel Rodriguez Barrios, RPh, MPH, MSc, Health Economics & Reimbursement Director Europe, Stryker, Madrid, Spain
Wen-Yi Shau, PhD, MD, Researcher, Center for Drug Evaluation, Taipei, Taiwan

Reference:
Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis


ISPOR Good Practices For Outcomes Research Index